Radar · Life Sciences in United Kingdom
Best Life Sciences Companies in United Kingdom
The 2540 best Life Sciences companies in United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Isomorphic Labs.
By Riya SenguptaFinancials
2540companies tracked
$32.2Bdisclosed funding
3unicorns
1151have raised
$32.2 billion in disclosed funding across 2,540 tracked companies tells you exactly how serious the United Kingdom's bet on Life Sciences has become. This directory ranks those companies by equity funding and recent momentum, so you can cut straight to who's actually capitalized. Isomorphic Labs sits at the top with $2.7B raised, a figure that dwarfs the rest of the field. Bit.bio has pulled in $186M. Storm Therapeutics and CellCentric aren't far behind. Three unicorns have emerged from this pool, backed by a mix of institutional and public capital including Ukri, Scottish Enterprise, and Oxford University Innovation.
Hot themes right now are stem cell banking, cell-based therapies, diagnostic biotechnology, and gene delivery systems, and I'd watch those clusters closely given where the funding is concentrating. Coverage has otherwise stayed flat. The global Life Sciences market is tracking toward a 10.2% CAGR, driven by an aging population and sustained institutional funding flows. What's worth noting for anyone scanning this list? The gap between the top filer and the median is enormous, which means the directory rewards careful filtering over broad scanning.
Sources & further reading
- New Drug Modalities 2025
- The Enduring Appeal of Swiss Manufacturing
- EU policy reforms and pharma investments highlight shifting industry priorities:
FLIAR INTELLIGENCE · LIFE SCIENCES × UNITED KINGDOM
Our analysis of 62 Life Sciences companies
$9.8b in tracked funding; 75% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2026.
62companies analysed
75%cloud-native stacks
2026funding peak (by rounds)
2unicorns
2016median founding year
683kcombined LinkedIn audience
47%of audience held by top 3
7companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in United Kingdom
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Isomorphic Labs Digital platform focused on revolutionizing drug discovery using AI 60Funding top 12%AI top 20%Innovation top 30%Patents top 33% All 11 signals ▾Fundingtop 12% AItop 20% Innovationtop 30% Patentstop 33% Moattop 39% Talentbottom 49% Growthbottom 47% Techbottom 46% Globalbottom 37% Marketbottom 36% Newsbottom 25% Funding: Raised $2.7B across 2 rounds · 2 rounds over 1 yrs (2.0/yr) AI: Classified as an AI company rank vs industry peers · Fliar Intelligence Index 60/100 | $2.7B | 1 mo ago | — | Demis Hassabis Founder & CEO | WebflowThree.jsGSAP+14 | — | 19 patents AI-driven drug discovery: protein‑ligand modeling, molecule property prediction, synthesis feasibility. | — |
| 2 | Nanopore Technologies Manufacturer of portable and benchtop devices for real-time DNA sequencing 87Tech top 11%Market top 21%Funding top 21%Talent top 24% All 9 signals ▾Techtop 11% Markettop 21% Fundingtop 21% Talenttop 24% Newstop 32% Growthtop 39% Moattop 39% Globaltop 42% Fin. healthtop 47% Tech: 82 technologies across 7/8 capability areas · Cloud: Amazon Cloudfront, Amazon S3 Market: 705 employees (top 2% of High Tech) · Revenue ~$234M rank vs industry peers · Fliar Intelligence Index 87/100 | $1.3B | 22 mo ago | 705 705 → 1,352 (+92%) · sector median +24% | Hagan Bayley Co-Founder | StoryblokContentfulSentry+30 | 13 signals ▲62% Leadership · Earnings | — | 1 launch |
| 3 | CMR Surgical 🦄 Developer of collaborative surgical robotic systems 72Patents top 12%Innovation top 19%Tech top 20%Moat top 22% All 12 signals ▾Patentstop 12% Innovationtop 19% Techtop 20% Moattop 22% Fundingtop 23% Talenttop 28% Producttop 31% Globaltop 32% Markettop 50% Fin. healthbottom 47% Growthbottom 40% Newsbottom 21% Patents: 1,253 patents matched (strict assignee match) · 778 filings since 2022 vs 475 in 2017-21 Innovation: 1,253 patents (top 1% of patent-holders) · 778 filings since 2022 vs 475 in 2017-21 rank vs industry peers · Fliar Intelligence Index 72/100 | $1.2B | 14 mo ago | 3 | Mark Slack Co-Founder & Chief Medical Officer | SentryTypeScriptGraphQL+7 | — | 1,253 patents Patents concentrated in health & consumer products | 2 job openings · 1 launch |
| 4 | Artios Developer of therapeutics targeting the deoxyribonucleic acid damage response in cancer 45Funding top 24%Talent top 28%Moat top 31%Tech top 49% All 8 signals ▾Fundingtop 24% Talenttop 28% Moattop 31% Techtop 49% Markettop 50% Growthbottom 46% Globalbottom 39% Fin. healthbottom 32% Funding: Raised $273M across 4 rounds · 4 rounds over 10 yrs (0.4/yr) Talent: 4 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 45/100 | $273M | 7 mo ago | 76 | Shweta Nair Founder | WordPressMySQLPHP+15 | — | — | — |
| 5 | Avacta Developer of drug delivery technology using tumor activated peptide linkers 24Funding top 21%News top 35%Moat top 38%Talent bottom 49% All 11 signals ▾Fundingtop 21% Newstop 35% Moattop 38% Talentbottom 49% Techbottom 47% Patentsbottom 42% Growthbottom 41% Globalbottom 41% Marketbottom 40% Innovationbottom 36% Fin. healthbottom 20% Funding: Raised $222M across 12 rounds · 12 rounds over 15 yrs (0.8/yr) News: 7 BI events in 12 mo (of 34 tracked, 8 types) · -46% YoY rank vs industry peers · Fliar Intelligence Index 24/100 | $222M | 7 mo ago | 90 90 → 47 (-48%) · sector median +24% | Christina Coughlin CEO | WordPressApple iCloud MailMicrosoft 365+17 | 7 signals ▼46% Funding · Announcements · Earnings | 17 patents Microfluidic reagent dispensing with optical/Raman detection for nucleic acid analysis | — |
| 6 | Avita Medical Regenerative and Respiratory Medicine product company 64Funding top 19%Market top 35%News top 35%Moat top 38% All 11 signals ▾Fundingtop 19% Markettop 35% Newstop 35% Moattop 38% Techtop 39% Talenttop 40% Growthtop 42% Globaltop 44% Fin. healthtop 48% Patentsbottom 45% Innovationbottom 42% Funding: Raised $205M across 13 rounds · 13 rounds over 17 yrs (0.8/yr) Market: 108 employees (top 17% of Life Sciences) · Revenue ~$71.6M rank vs industry peers · Fliar Intelligence Index 64/100 | $205M | 10 mo ago | 108 108 → 255 (+136%) · sector median +24% | Michael Perry CEO | DrupalApple iCloud MailPHP+35 | 17 signals ▲21% Earnings · Leadership · Capital raise | 26 patents Automated tissue processing and cell suspension preparation for regenerative cell therapies | 1 partnership |
| 7 | Touchlight 🦄 Provider of cell-free DNA technology platform for genetic medicine application 60Moat top 22%Patents top 28%Talent top 28%Funding top 29% All 11 signals ▾Moattop 22% Patentstop 28% Talenttop 28% Fundingtop 29% Techtop 30% Innovationtop 39% Markettop 41% Growthbottom 49% Globalbottom 49% Fin. healthbottom 30% Newsbottom 22% Moat: Editorial + unicorn rating 9/10 · IP moat: 106 patents Patents: 106 patents matched (strict assignee match) · 52 filings since 2022 vs 50 in 2017-21 rank vs industry peers · Fliar Intelligence Index 60/100 | $190M | 8 mo ago | 158 158 → 161 (+2%) · sector median +24% | Jonny Ohlson Founder & Co-CEO | WordPressMySQLPHP+33 | — | 106 patents Patents concentrated in chemistry & materials | 4 launchs |
| 8 | Bit.bio Manufacturer of programmed human cells for research and drug discovery 74Growth top 17%Funding top 23%News top 29%Moat top 31% All 9 signals ▾Growthtop 17% Fundingtop 23% Newstop 29% Moattop 31% Fin. healthtop 38% Talenttop 38% Markettop 44% Techbottom 48% Globalbottom 39% Growth: Headcount 13 → 52 (+300%) across vintages · Revenue +41% YoY Funding: Raised $186M across 7 rounds · 7 rounds over 9 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 74/100 | $186M | 5 mo ago | 52 | Mark Kotter Co-Founder | Cart FunctionalityHubSpot CMS HubApple iCloud Mail+20 | 4 signals ▲300% Funding · Layoffs | — | 3 launchs |
| 9 | Mission Therapeutics Developer of small molecule inhibitors targeting specific disease associated enzymes 53Funding top 26%Moat top 26%Patents top 29%Innovation top 35% All 10 signals ▾Fundingtop 26% Moattop 26% Patentstop 29% Innovationtop 35% Talenttop 38% Growthtop 48% Markettop 50% Globalbottom 42% Fin. healthbottom 31% Newsbottom 21% Funding: Raised $179M across 9 rounds · 9 rounds over 15 yrs (0.6/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 305 patents rank vs industry peers · Fliar Intelligence Index 53/100 | $179M | 8 mo ago | 45 | Keith Menear Co-Founder | — | — | 305 patents Small-molecule USP30 deubiquitinase inhibitors for mitochondrial disease, cancer, and fibrosis | — |
| 10 | Nuclera Provider of rapid protein expression and screening systems for biotechnology labs 72Patents top 15%Innovation top 17%Funding top 26%Moat top 26% All 11 signals ▾Patentstop 15% Innovationtop 17% Fundingtop 26% Moattop 26% Growthtop 27% Talenttop 38% Techtop 42% Fin. healthtop 44% Newsbottom 44% Globalbottom 44% Marketbottom 40% Patents: 140 patents matched (strict assignee match) · 140 filings since 2022 vs 0 in 2017-21 Innovation: 140 patents (top 20% of patent-holders) · 140 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 72/100 | $164M | 6 mo ago | 26 | Michael Chen Co-Founder & CEO | Cart FunctionalityWordPressApple iCloud Mail+34 | 3 signals ▼40% Capital raise · Funding | 140 patents Enables high-throughput protein assays on digital microfluidic platforms. | 2 job openings |
| 11 | Owlstone Medical Developer of non-invasive breath-based diagnostics for cancer and infectious diseases 67Funding top 18%Moat top 28%Product top 36%Talent top 38% All 9 signals ▾Fundingtop 18% Moattop 28% Producttop 36% Talenttop 38% Growthtop 40% Markettop 44% Techtop 44% Globalbottom 45% Newsbottom 18% Funding: Raised $150M across 16 rounds · 16 rounds over 15 yrs (1.1/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 67/100 | $150M | 8 mo ago | 199 199 → 147 (-26%) · sector median +24% | David Alonso Co-Founder & COO | WordPress Block EditorWordPressMySQL+30 | — | — | 1 job opening |
| 12 | Draigtherapeutics Developer of targeted neuromodulators for neuropsychiatric disorders treatment 35Funding top 25%Moat top 35%Talent top 38%Global top 45% All 6 signals ▾Fundingtop 25% Moattop 35% Talenttop 38% Globaltop 45% Techbottom 36% Marketbottom 31% Funding: Raised $140M across 1 rounds · 1 rounds over 2 yrs (0.5/yr) Moat: Soonicorn · 5 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 35/100 | $140M | 12 mo ago | — | Simon Ward Co-Founder | WordPressApple iCloud MailMicrosoft 365+14 | — | — | — |
| 13 | Tissue Regenix Developer of regenerative medical devices by using cell technology 40Funding top 17%Moat top 38%Patents top 39%Talent top 44% All 10 signals ▾Fundingtop 17% Moattop 38% Patentstop 39% Talenttop 44% Techtop 45% Innovationtop 50% Growthbottom 47% Newsbottom 47% Globalbottom 47% Marketbottom 27% Funding: Raised $128M across 5 rounds · 5 rounds over 11 yrs (0.5/yr) Moat: Editorial + unicorn rating 5/10 · IP moat: 28 patents rank vs industry peers · Fliar Intelligence Index 40/100 | $128M | 5 mo ago | 7 | Steve Couldwell CEO | WordPress Block EditorWordPressMySQL+21 | 4 signals ▼64% Leadership · Regulatory | 28 patents Decellularized tissue scaffolds for regenerative medicine and tissue engineering | — |
| 14 | Trogenix Developer of precision cancer treatments using its proprietary gene therapy platform 55Funding top 23%Growth top 28%Talent top 38%Moat top 40% All 7 signals ▾Fundingtop 23% Growthtop 28% Talenttop 38% Moattop 40% Techbottom 47% Globalbottom 45% Marketbottom 35% Funding: Raised $111M across 3 rounds · 3 rounds over 2 yrs (1.5/yr) Growth: Web rank 50,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 55/100 | $111M | 8 mo ago | — | Steve Pollard Co-Founder | WordPressMySQLPHP+22 | — | — | 1 launch |
| 15 | Automata Developer of modular lab automation platforms for biological research workflows 64Funding top 25%Product top 25%Tech top 27%Moat top 31% All 11 signals ▾Fundingtop 25% Producttop 25% Techtop 27% Moattop 31% Innovationtop 32% Fin. healthtop 33% Newstop 43% Growthtop 48% Talentbottom 49% Marketbottom 44% Globalbottom 39% Funding: Raised $107M across 8 rounds · 8 rounds over 11 yrs (0.7/yr) Product: 7 distinct product lines · Company stage: Series C rank vs industry peers · Fliar Intelligence Index 64/100 | $107M | 4 mo ago | 40 | Mostafa ElSayed Co-Founder & CEO | WordPress Block EditorWordPressApple iCloud Mail+33 | — | — | 1 partnership |
| 16 | STORM Therapeutics Developer of small molecule inhibitors targeting enzymes that modify RNA 50Funding top 26%Moat top 28%Talent top 28%Patents top 30% All 11 signals ▾Fundingtop 26% Moattop 28% Talenttop 28% Patentstop 30% Innovationtop 36% Newstop 43% Growthtop 45% Marketbottom 46% Globalbottom 42% Fin. healthbottom 39% Techbottom 30% Funding: Raised $98.3M across 8 rounds · 8 rounds over 11 yrs (0.7/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 44 patents rank vs industry peers · Fliar Intelligence Index 50/100 | $98M | 2 mo ago | 28 28 → 14 (-50%) · sector median +24% | Eric Miska Co-Founder & Director | ProcessWirePHPApache HTTP Server+6 | — | 44 patents Small‑molecule METTL3 inhibitors for epigenetic cancer therapeutics | — |
| 17 | CellCentric Developer of oral small molecule inhibitors for treating blood cancers 50Funding top 21%Talent top 32%News top 33%Growth top 35% All 11 signals ▾Fundingtop 21% Talenttop 32% Newstop 33% Growthtop 35% Patentstop 39% Moattop 43% Partnersbottom 49% Innovationbottom 48% Techbottom 45% Globalbottom 44% Marketbottom 35% Funding: Raised $90.3M across 8 rounds · 8 rounds over 23 yrs (0.3/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 50/100 | $90M | 1 mo ago | 18 | Azim Surani Co-Founder | WordPressMySQLPHP+20 | 6 signals ▲50% Leadership · Capital raise · Contracts | 86 patents Small-molecule epigenetic modulators of p300/CBP acetyltransferase enzymes | 1 launch |
| 18 | Immutrin Biotechnology company developing next‑generation antibody therapies 45Funding top 23%Patents top 47%Talent bottom 49%Global bottom 48% All 5 signals ▾Fundingtop 23% Patentstop 47% Talentbottom 49% Globalbottom 48% Innovationbottom 45% Funding: Raised $86.9M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Patents: 6 patents matched (strict assignee match) · 6 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 45/100 | $87M | 2 mo ago | — | Mihriban Tuna Chief Executive Officer | — | — | 6 patents Monoclonal antibodies targeting multiple amyloid fibril types for therapeutic use | — |
| 19 | Portage Biotech Therapeutics based on Cell Permeable Peptide Platform 53Funding top 22%Tech top 41%Market top 44%Talent bottom 49% All 7 signals ▾Fundingtop 22% Techtop 41% Markettop 44% Talentbottom 49% Globalbottom 43% Growthbottom 42% Newsbottom 27% Funding: Raised $84.0M across 6 rounds · 6 rounds over 11 yrs (0.5/yr) Tech: 42 technologies across 4/8 capability areas · Cloud: Akamai, Amazon Web Services rank vs industry peers · Fliar Intelligence Index 53/100 | $84M | 9 mo ago | 205 | Alexander Pickett CEO | DrupalPHPZURB Foundation+24 | — | — | — |
| 20 | Cytospire Therapeutics Provider of immune cell engagers for treating cancer 53Funding top 24%Global top 45%Talent bottom 49% All 3 signals ▾Fundingtop 24% Globaltop 45% Talentbottom 49% Funding: Raised $83.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Global: Investors from 4 countries beyond United Kingdom rank vs industry peers · Fliar Intelligence Index 53/100 | $83M | 1 mo ago | — | Natalie Mount CEO | — | — | — | 1 award |
| 21 | Alchemab Developer of antibody therapeutics for treating oncology and neurodegenerative conditions 45Funding top 28%Talent top 28%Moat top 31%Growth top 35% All 7 signals ▾Fundingtop 28% Talenttop 28% Moattop 31% Growthtop 35% Globalbottom 37% Marketbottom 34% Techbottom 33% Funding: Raised $82.7M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) Talent: 4 named leaders on record · 4 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 45/100 | $83M | 9 mo ago | 8 | Jane Osbourn Co-Founder & CEO | WordPress Block EditorWordPressMySQL+14 | — | — | — |
| 22 | Charm Therapeutics Developer of menin inhibitors designed for acute myeloid leukemia treatment 50Funding top 24%News top 29%Moat top 31%Growth top 32% All 8 signals ▾Fundingtop 24% Newstop 29% Moattop 31% Growthtop 32% Talenttop 33% Techbottom 49% Globalbottom 37% Marketbottom 29% Funding: Raised $70.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) News: 4 BI events in 12 mo (of 8 tracked, 3 types) · +300% YoY rank vs industry peers · Fliar Intelligence Index 50/100 | $70M | 9 mo ago | 16 16 → 32 (+100%) · sector median +24% | Laksh Aithani Co-Founder & CEO | WordPressMySQLPHP+22 | 4 signals ▲300% Funding · Capital raise | — | — |
| 23 | Enterobiotix Developer of microbiome-based therapeutics for multiple disease targets 50Growth top 13%Funding top 25%Product top 30%Moat top 39% All 11 signals ▾Growthtop 13% Fundingtop 25% Producttop 30% Moattop 39% Talentbottom 49% Globalbottom 42% Innovationbottom 41% Techbottom 41% Patentsbottom 37% Marketbottom 36% Newsbottom 22% Growth: Headcount 11 → 28 (+155%) across vintages · Fresh capital in last 24 mo Funding: Raised $66.0M across 10 rounds · 10 rounds over 9 yrs (1.1/yr) rank vs industry peers · Fliar Intelligence Index 50/100 | $66M | 1 mo ago | 28 28 → 44 (+57%) · sector median +24% | James McIlroy Founder & CEO | Cart FunctionalitySquarespace CommerceSquarespace+13 | — | 10 patents Medical sample collection containers for diagnostic testing | 1 award |
| 24 | Relation AI-based drug development tools for researchers 55Funding top 25%Talent top 28%AI top 30%Growth top 35% All 8 signals ▾Fundingtop 25% Talenttop 28% AItop 30% Growthtop 35% Moattop 36% Techbottom 43% Globalbottom 37% Marketbottom 27% Funding: Raised $65.3M across 5 rounds · 5 rounds over 5 yrs (1.0/yr) Talent: 4 named leaders on record · 4 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 55/100 | $65M | 6 mo ago | 12 | Jake Taylor-King Co-Founder & Chief Innovation Officer | Craft CMSApple iCloud MailGoogle Workspace+11 | — | — | 1 partnership · 1 award |
| 25 | Centauri Therapeutics Developer of immunotherapeutics to treat infectious diseases 35Funding top 26%Growth top 35%Moat top 36%Patents top 46% All 9 signals ▾Fundingtop 26% Growthtop 35% Moattop 36% Patentstop 46% Talentbottom 49% Innovationbottom 42% Globalbottom 42% Techbottom 41% Marketbottom 25% Funding: Raised $64.9M across 12 rounds · 12 rounds over 11 yrs (1.1/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 35/100 | $65M | 3 mo ago | 6 | Jennifer Schneider CEO | WordPress Block EditorWordPressMySQL+15 | — | 50 patents Patents concentrated in chemistry & materials | — |
| 26 | Engitix Developer of technology for in vitro drug discovery 42Growth top 35%Talent top 38%Funding top 39%News top 43% All 10 signals ▾Growthtop 35% Talenttop 38% Fundingtop 39% Newstop 43% Patentstop 44% Moattop 47% Techtop 50% Innovationbottom 43% Globalbottom 42% Marketbottom 32% Growth: Fresh capital in last 24 mo Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 42/100 | $60M | 5 mo ago | 16 | Massimo Pinzani Co-Founder | WebflowApple iCloud MailGSAP+11 | — | 4 patents Patents concentrated in chemistry & materials | 1 partnership |
| 27 | CoMind Provider of a non-invasive brain-computer interface solution for various industries 55Growth top 11%News top 24%Funding top 29%Moat top 42% All 9 signals ▾Growthtop 11% Newstop 24% Fundingtop 29% Moattop 42% Partnerstop 45% Talentbottom 49% Marketbottom 38% Globalbottom 37% Techbottom 36% Growth: Headcount 15 → 36 (+140%) across vintages · Fresh capital in last 24 mo News: 7 BI events in 12 mo (of 7 tracked, 2 types) · 4 high-value events (IPO/M&A/funding/contracts) in 12 mo rank vs industry peers · Fliar Intelligence Index 55/100 | $60M | 7 mo ago | 36 36 → 81 (+125%) · sector median +24% | James Dacombe Co-Founder & CEO | Framer SitesApple iCloud MailGoogle Workspace+8 | 7 signals Funding · Regulatory | — | — |
| 28 | T-Therapeutics Developer of T-cell-based rtherapeutics for cancer treatment 62Patents top 12%Innovation top 19%Moat top 26%News top 27% All 10 signals ▾Patentstop 12% Innovationtop 19% Moattop 26% Newstop 27% Fundingtop 30% Growthtop 32% Talenttop 38% Techbottom 47% Globalbottom 45% Marketbottom 32% Patents: 239 patents matched (strict assignee match) · 105 filings since 2022 vs 14 in 2017-21 Innovation: 239 patents (top 11% of patent-holders) · 105 filings since 2022 vs 14 in 2017-21 rank vs industry peers · Fliar Intelligence Index 62/100 | $59M | 7 mo ago | — | Haydn Prosser Co-Founder & Director | WordPressMySQLPHP+21 | 5 signals Funding | 239 patents Therapeutic nucleic acid agents for gene expression inhibition (antisense, siRNA, oligonucleotide conjugates). | 1 job opening |
| 29 | Lightcast Developer of single-cell functional analysis using a droplet-based platform 35Funding top 28%Growth top 36%Talent top 38%Moat bottom 48% All 8 signals ▾Fundingtop 28% Growthtop 36% Talenttop 38% Moatbottom 48% Techbottom 46% Globalbottom 39% Marketbottom 30% Fin. healthbottom 22% Funding: Raised $49.0M across 7 rounds · 7 rounds over 3 yrs (2.3/yr) Growth: Headcount 10 → 25 (+150%) across vintages · Revenue -5% YoY rank vs industry peers · Fliar Intelligence Index 35/100 | $49M | 2 mo ago | 25 | Cameron Frayling Founder | WebflowReactTermly+10 | — | — | — |
| 30 | Mestag Therapeutics Developer of therapeutics for the treatment of cancer and inflammatory diseases 35Talent top 23%Funding top 28%Moat top 39%Tech bottom 46% All 6 signals ▾Talenttop 23% Fundingtop 28% Moattop 39% Techbottom 46% Globalbottom 37% Marketbottom 26% Talent: 6 named leaders on record · 6 C-suite/founder profiles curated Funding: Raised $45.0M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $45M | 3 mo ago | 8 | David Tuveson Co-Founder | WordPressMySQLPHP+17 | — | — | — |
| 31 | Chemify Developer of a platform for digitizing chemistry and chemical discovery 64Growth top 20%Funding top 26%AI top 30%Tech top 40% All 11 signals ▾Growthtop 20% Fundingtop 26% AItop 30% Techtop 40% Talentbottom 49% Marketbottom 44% Globalbottom 42% Moatbottom 42% Patentsbottom 40% Innovationbottom 39% Newsbottom 17% Growth: Web rank 50,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo Funding: Raised $43.0M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 64/100 | $43M | 4 mo ago | 40 | Lee Cronin Founder & CEO | Node.jsUbuntuTailwind CSS+9 | — | 2 patents Modular catalytic reactors and networked chemical processing platforms for scalable synthesis | — |
| 32 | Cellular Origins Provider of automated manufacturing solution for cell and gene therapy 53Patents top 31%Innovation top 32%Funding top 34%Growth top 35% All 10 signals ▾Patentstop 31% Innovationtop 32% Fundingtop 34% Growthtop 35% Moattop 38% Techtop 46% Talentbottom 49% Globalbottom 40% Marketbottom 32% Newsbottom 17% Patents: 39 patents matched (strict assignee match) · 39 filings since 2022 vs 0 in 2017-21 Innovation: 39 patents (top 53% of patent-holders) · 39 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 53/100 | $40M | 6 mo ago | — | Edwin Stone Founder & CEO | WordPressMySQLPHP+21 | — | 39 patents Single-use bioprocessing hardware: bag cartridges, automated fluid handling, peristaltic pumps. | 1 launch · 1 partnership |
| 33 | Theolytics Developer of oncolytic adenovirus for the treatment of cancer 53Growth top 20%Funding top 29%Patents top 39%Moat top 42% All 10 signals ▾Growthtop 20% Fundingtop 29% Patentstop 39% Moattop 42% Innovationtop 50% Talentbottom 49% Techbottom 47% Globalbottom 42% Marketbottom 35% Newsbottom 18% Growth: Headcount 16 → 26 (+62%) across vintages · Fresh capital in last 24 mo Funding: Raised $33.6M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 53/100 | $34M | 3 mo ago | 26 26 → 30 (+15%) · sector median +24% | Charlotte Casebourne Co-Founder & CEO | WixSentryBootstrap+12 | — | 14 patents Oncolytic adenovirus vectors for cancer gene therapy and virotherapy | 1 job opening |
| 34 | TympaHealth Provider of an AI-based hearing health diagnosis device for medical professionals 57Growth top 28%Funding top 32%Talent top 33%Tech top 41% All 8 signals ▾Growthtop 28% Fundingtop 32% Talenttop 33% Techtop 41% AItop 45% Productbottom 48% Globalbottom 37% Marketbottom 25% Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo Funding: Raised $31.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 57/100 | $31M | 0 mo ago | 7 | Krishan Ramdoo Founder & CEO | WordPressApple iCloud MailMicrosoft 365+22 | — | — | — |
| 35 | Alesi Surgical Developer of surgical smoke elimination systems for open and laparoscopic procedures 21Product top 32%Funding top 35%Patents top 36%Innovation top 37% All 10 signals ▾Producttop 32% Fundingtop 35% Patentstop 36% Innovationtop 37% Techtop 45% Moattop 45% Globalbottom 42% Growthbottom 38% Marketbottom 18% Fin. healthbottom 13% Product: 4 distinct product lines · 1 published app (300 installs) Funding: Raised $27.7M across 8 rounds · 8 rounds over 16 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 21/100 | $28M | 1 mo ago | 7 | — | WordPressMySQLPHP+24 | — | 81 patents Electrosurgical and energy‑based surgical instruments for tissue cutting, sealing, and ablation | — |
| 36 | Cirdan Imaging Laboratory Information System for clinical laboratories 53Product top 30%Growth top 31%Moat top 37%Talent top 38% All 12 signals ▾Producttop 30% Growthtop 31% Moattop 37% Talenttop 38% Fundingtop 39% Fin. healthtop 45% Techbottom 47% Marketbottom 46% Globalbottom 45% Innovationbottom 44% Patentsbottom 33% Newsbottom 20% Product: 4 distinct product lines · Company stage: Series B Growth: Revenue +39% YoY · Web rank 50,000,000 → 10,000,000 YoY rank vs industry peers · Fliar Intelligence Index 53/100 | $24M | 2 mo ago | 84 | Cahal Cormican Co-Founder | WordPressMySQLPHP+18 | — | 6 patents Patents concentrated in health & consumer products | — |
| 37 | Techspert Leading expert network for healthcare and life sciences 60Funding top 29%Tech top 30%Growth top 32%Moat top 39% All 7 signals ▾Fundingtop 29% Techtop 30% Growthtop 32% Moattop 39% Talentbottom 49% Globalbottom 46% Marketbottom 42% Funding: Raised $18.1M across 4 rounds · 4 rounds over 8 yrs (0.5/yr) Tech: 43 technologies across 5/8 capability areas · Cloud: Amazon Cloudfront, Amazon S3 rank vs industry peers · Fliar Intelligence Index 60/100 | $18M | 3 mo ago | 53 53 → 71 (+34%) · sector median +24% | David Holden Co-Founder & CEO | HubSpot CMS HubSalesforceBootstrap+25 | — | — | — |
| 38 | Endlyz Developer of small-molecule therapeutics targeting lysosomal dysfunction in neurodegenerative diseases 24Funding top 32%Tech bottom 49%Talent bottom 49%Global bottom 48% All 5 signals ▾Fundingtop 32% Techbottom 49% Talentbottom 49% Globalbottom 48% Marketbottom 25% Funding: Raised $17.3M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Tech: 13 technologies across 4/8 capability areas · Cloud: Vercel rank vs industry peers · Fliar Intelligence Index 24/100 | $17M | 2 mo ago | — | Joanna Wolak Co-Founder & CEO | Node.jsTailwind CSSReact+10 | — | — | — |
| 39 | GripAble Provider of cloud-based rehabilitation device with a companion app for the patients 53Growth top 21%Funding top 32%AI top 45%Talent bottom 49% All 8 signals ▾Growthtop 21% Fundingtop 32% AItop 45% Talentbottom 49% Productbottom 48% Techbottom 45% Globalbottom 37% Marketbottom 27% Growth: Headcount 11 → 27 (+145%) across vintages · Fresh capital in last 24 mo Funding: Raised $16.5M across 6 rounds · 6 rounds over 9 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 53/100 | $17M | 3 mo ago | 27 27 → 17 (-37%) · sector median +24% | Mike Mace CTO - Cofounder | WordPressMySQLSalesforce+22 | — | — | — |
| 40 | I Q Endoscopes Manufacturer of endoscope devices for healthcare sector 35Funding top 38%Moat top 45%Patents top 50%Innovation bottom 49% All 8 signals ▾Fundingtop 38% Moattop 45% Patentstop 50% Innovationbottom 49% Talentbottom 49% Marketbottom 40% Globalbottom 37% Newsbottom 22% Funding: Raised $13.9M across 3 rounds · 3 rounds over 6 yrs (0.5/yr) Moat: Editorial + unicorn rating 1/10 · IP moat: 43 patents rank vs industry peers · Fliar Intelligence Index 35/100 | $14M | 3 mo ago | 24 | Matt Ginn CEO | — | — | 43 patents Advanced imaging and illumination components for flexible medical endoscope systems | — |
| 41 | Oxford Drug Design Provider of computer-aided design of antibiotics for MDR infections 32Talent top 28%Funding top 30%Moat top 32%Patents top 38% All 9 signals ▾Talenttop 28% Fundingtop 30% Moattop 32% Patentstop 38% Innovationtop 40% Producttop 41% Globalbottom 40% Marketbottom 26% Techbottom 23% Talent: Analyst team rating 4/5 · 3 named leaders on record Funding: Raised $12.4M across 7 rounds · 7 rounds over 9 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 32/100 | $12M | 4 mo ago | 9 | Graham Richards Founder & Chairman | — | — | 46 patents Antibacterial aminoacyl‑tRNA synthetase inhibitors based on sulfonamide/aryl‑sulfinyl scaffolds | — |
| 42 | Lucida Medical Developer of MRI-based cancer screening technology using artificial intelligence (AI) 35Talent top 38%Funding top 44%AI top 45%Moat top 48% All 7 signals ▾Talenttop 38% Fundingtop 44% AItop 45% Moattop 48% Techbottom 48% Globalbottom 37% Marketbottom 27% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $11.5M across 1 rounds · 1 rounds over 5 yrs (0.2/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $12M | 2 mo ago | 12 12 → 29 (+142%) · sector median +24% | Evis Sala Co-Founder | WordPressMySQLPHP+21 | — | — | — |
| 43 | Antiverse Developer of computational platform for de novo design of antibody therapeutics 48AI top 30%Tech top 32%Talent top 34%Funding top 39% All 8 signals ▾AItop 30% Techtop 32% Talenttop 34% Fundingtop 39% Moattop 48% Newsbottom 41% Globalbottom 39% Marketbottom 22% AI: Classified as an AI company · Product described with: machine learning Tech: 35 technologies across 5/8 capability areas · Cloud: Cloudflare rank vs industry peers · Fliar Intelligence Index 48/100 | $10M | 3 mo ago | 7 | Murat Tunaboylu Co-Founder & CEO | WebflowApple iCloud MailGoogle Workspace+19 | — | — | — |
| 44 | Neutonic Retailer of nootropic drinks, supplements, and related accessories online 69Growth top 28%Talent top 28%Tech top 34%Funding top 43% All 5 signals ▾Growthtop 28% Talenttop 28% Techtop 34% Fundingtop 43% Globalbottom 25% Growth: Web rank 5,000,000 → 1,000,000 YoY · Fresh capital in last 24 mo Talent: 4 named leaders on record · 4 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 69/100 | $10M | 1 mo ago | — | James Smith Co-Founder | Cart FunctionalityShopifyBootstrap+31 | — | — | — |
| 45 | iFAST Diagnostics Standalone pathology laboratory center 40News top 24%Growth top 25%Talent top 33%Funding top 47% All 9 signals ▾Newstop 24% Growthtop 25% Talenttop 33% Fundingtop 47% Techbottom 48% Productbottom 39% Innovationbottom 37% Globalbottom 37% Marketbottom 17% News: 10 BI events in 12 mo (of 26 tracked, 5 types) · +233% YoY Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 40/100 | $9M | 0 mo ago | 6 | Hywel Morgan Co-Founder & CTO | WordPressMySQLPHP+19 | 10 signals ▲233% Earnings · Leadership | — | 1 partnership · 2 awards |
| 46 | Plaquetec Developer of a method to profile the biology of coronary artery 22Talent top 28%Moat top 39%Product top 41%News top 43% All 10 signals ▾Talenttop 28% Moattop 39% Producttop 41% Newstop 43% Patentstop 45% Fundingtop 49% Techbottom 49% Innovationbottom 47% Globalbottom 42% Marketbottom 15% Talent: Analyst team rating 4/5 Moat: Editorial + unicorn rating 3/10 · IP moat: 44 patents rank vs industry peers · Fliar Intelligence Index 22/100 | $8M | 1 mo ago | 2 | — | WixSentryBootstrap+11 | — | 44 patents Vascular catheter systems for intravascular sampling and biomarker‑based prognosis | — |
| 47 | Scarlet Therapeutics Developer of cell-based therapeutics to treat a wide range of diseases 14Talent top 28%Funding bottom 47%Global bottom 37%Market bottom 18% All 4 signals ▾Talenttop 28% Fundingbottom 47% Globalbottom 37% Marketbottom 18% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $7.1M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 14/100 | $7M | 1 mo ago | 3 | Jan Frayne Co-Founder & CTO | — | — | — | 1 job opening |
| 48 | Infex Therapeutics Developer of drugs for treating multiple infectious diseases 37Patents top 27%Innovation top 33%Funding top 44%Moat top 45% All 8 signals ▾Patentstop 27% Innovationtop 33% Fundingtop 44% Moattop 45% Talentbottom 49% Globalbottom 44% Techbottom 37% Marketbottom 32% Patents: 60 patents matched (strict assignee match) · 50 filings since 2022 vs 10 in 2017-21 Innovation: 60 patents (top 42% of patent-holders) · 50 filings since 2022 vs 10 in 2017-21 rank vs industry peers · Fliar Intelligence Index 37/100 | $6M | 1 mo ago | 23 23 → 24 (+4%) · sector median +24% | Pete Jackson CEO | WordPressMySQLPHP+19 | — | 60 patents Small-molecule antivirals and metallo‑beta‑lactamase inhibitors for infectious diseases | — |
| 49 | Imperagen Developer of enzyme engineering platform for drug development 16Talent top 28%Funding top 49%Tech bottom 44%Global bottom 29% All 5 signals ▾Talenttop 28% Fundingtop 49% Techbottom 44% Globalbottom 29% Marketbottom 17% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $4.3M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 16/100 | $4M | 0 mo ago | 5 | Timothy Eyes Co-Founder | Radix UITailwind CSSshadcn/ui+9 | — | — | — |
| 50 | Garland Surgical Developer of surgical implants for hip replacement 9Funding bottom 49%Talent bottom 49%Global bottom 36%Market bottom 18% All 4 signals ▾Fundingbottom 49% Talentbottom 49% Globalbottom 36% Marketbottom 18% Funding: Raised $4.1M across 2 rounds · 2 rounds over 1 yrs (2.0/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 9/100 | $4M | 1 mo ago | 3 | Simon Mifsud Founder & CEO | — | — | — | — |
Top 12 Life Sciences companies in United Kingdom
#1
Series B · London, England · founded 2021$2.7Braised▾
Series B · London, England · founded 2021
Digital platform focused on revolutionizing drug discovery using AI. The company's computational tools analyze complex biological phenomena to assist in the design of molecules. The technology predicts how potential therapeutic compounds perform to facilitate the development of treatments for various diseases.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Funding
top 12%AI
top 20%Innovation
top 30%Patents
top 33%Moat
top 39%Talent
bottom 49%Funding: Raised $2.7B across 2 rounds · 2 rounds over 1 yrs (2.0/yr) · Last round Series B (May 2026)
AI: Classified as an AI company
Innovation: 19 patents (top 47% of patent-holders) · 19 filings since 2022 vs 0 in 2017-21 · Deep-tech classification: Artificial Intelligence
Audience (LinkedIn): 95k LinkedIn followers — 13.9% of this cohort's audience
Funding rounds
- May 2026Series B$2.1B
- Mar 2025Series A$600M
Founders & team
Investors
Thrive Capital, Google Ventures, Alphabet, MGX, Temasek, CapitalG
Tech stack
<Model-Viewer>CloudflareCookiebotGoogle AnalyticsGoogle Hosted LibrariesGsap
#2
Series D · Cambridge, England · founded 2003 · 18 employees$90.3Mraised▾
Series D · Cambridge, England · founded 2003 · 18 employees
Developer of oral small molecule inhibitors for treating blood cancers. This pharmaceutical entity focuses on creating therapeutic agents that target specific proteins involved in tumor progression. The research involves modulating gene expression by disrupting the interaction of transcription co-activation factors within cancer cells. The primary therapeutic candidate is designed to address multiple myeloma and other hematological malignancies by binding to bromodomains. This approach aims to reduce the production of proteins that drive tumor growth. The development process includes clinical evaluation to assess safety and efficacy across various patient populations.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 21%Talent
top 32%News
top 33%Growth
top 35%Patents
top 39%Moat
top 43%Funding: Raised $90.3M across 8 rounds · 8 rounds over 23 yrs (0.3/yr) · Last round Series D (May 2026)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated · 4 leadership moves in 12 mo
News: 6 BI events in 12 mo (of 18 tracked, 6 types) · +50% YoY · 1 high-value events (IPO/M&A/funding/contracts) in 12 mo
Audience (LinkedIn): 7k LinkedIn followers
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- May 2026Series D$220M
- May 2025Series C$120M
- Jul 2024Series C$35M
- Jul 2023Series C$25M
Founders & team
Investors
Takeda Ventures, Morningside, Nesta Impact Investments, Providence Investment Company, UK Innovation Science & Seed Fund, RA Capital Management
Tech stack
CloudflareCloudflare Browser InsightsCookieyesCore-JsDocusignElementor
#3
Series C · Waterbeach, Cambridgeshire · founded 2015 · 28 employees$98.3Mraised▾
Series C · Waterbeach, Cambridgeshire · founded 2015 · 28 employees
Developer of small molecule inhibitors targeting enzymes that modify RNA. These therapeutic agents focus on regulating protein synthesis by modulating the activity of enzymes involved in ribonucleic acid modification. The research and development efforts center on clinical applications for treating various forms of cancer. By targeting specific biological pathways, these inhibitors aim to influence cellular decision-making processes. The development pipeline includes candidates currently undergoing clinical evaluation to assess safety and efficacy in human subjects.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 26%Moat
top 28%Talent
top 28%Patents
top 30%Innovation
top 36%News
top 43%Funding: Raised $98.3M across 8 rounds · 8 rounds over 11 yrs (0.7/yr) · Last round Series C (Apr 2026)
Moat: Editorial + unicorn rating 8/10 · IP moat: 44 patents · Soonicorn
Talent: Analyst team rating 4/5 · 3 named leaders on record · 3 C-suite/founder profiles curated
Audience (LinkedIn): 10k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. Alida Biosciences) announced in 12 mo
Funding rounds
- Apr 2026Series C$56M
- Dec 2022Series B$30M
- May 2022Grant (prize money)—
- Jan 2020Series A$10M
Founders & team
Investors
Taiho Ventures, Seroba Life Sciences, Cambridge Innovation Capital, M Ventures, Pfizer Venture Investments, IP Group
Tech stack
Apache Http ServerFont AwesomeGodaddyGoogle AnalyticsHstsJquery
#4
Series B · Edinburgh, Scotland · founded 2017 · 28 employees$66Mraised▾
Series B · Edinburgh, Scotland · founded 2017 · 28 employees
Developer of microbiome-based therapeutics for multiple disease targets. The company is engaged in developing an integrated anaerobic system which comprises of a closed system collection and processing benchtop system that will allow therapies to be produced outside of cleanrooms and in anaerobic environments. It aims to offer microbiome therapy to patients suffering from Inflammatory Bowel Disease and other diseases related to the gut.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Growth
top 13%Funding
top 25%Product
top 30%Moat
top 39%Talent
bottom 49%Global
bottom 42%Growth: Headcount 11 → 28 (+155%) across vintages · Fresh capital in last 24 mo
Funding: Raised $66.0M across 10 rounds · 10 rounds over 9 yrs (1.1/yr) · Last round Series B (Apr 2026)
Product: 4 distinct product lines · Company stage: Series B
Audience (LinkedIn): 8k LinkedIn followers
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Apr 2026Series B$25M
- Mar 2026Series B$5.3M
- Jul 2025Series B$1.4M
- Mar 2024Series B$1.3M
Founders & team
Investors
Equity Gap, BWC, University of Aberdeen, Scottish Investment Bank, SIS Ventures, Syndicate Room
Tech stack
AngularApple Icloud MailCart FunctionalityCore-JsGodaddyHsts
#5
Series A · London, England · founded 2023$83Mraised▾
Series A · London, England · founded 2023
Provider of immune cell engagers for treating cancer. It offers a portfolio of differentiated multispecific engager antibodies to enhance and direct the activity of innate and adaptive effector immune cells to discriminate between target diseased vs healthy cell for the treatment of solid tumors and other cancer.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Funding
top 24%Global
top 45%Talent
bottom 49%Funding: Raised $83.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series A (May 2026)
Global: Investors from 4 countries beyond United Kingdom
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 2k LinkedIn followers
Activity (LinkedIn): 2 awards announced in 12 mo
Funding rounds
- May 2026Series A$83M
- Seed—
Founders & team
Investors
4Bio Capital, Servier, British Business Bank, Sound Bioventures, Criteria Bio Ventures, Abingworth
#6
Series C · Cambridge, England · founded 2016 · 52 employees$186.1Mraised▾
Series C · Cambridge, England · founded 2016 · 52 employees
Manufacturer of programmed human cells for research and drug discovery. This entity utilizes gene-targeting technology to express transcription factors that reprogram induced pluripotent stem cells into defined human cell types. These products include various nerve, immune, and muscle cell lines designed for use in laboratory assays, disease modeling, and therapeutic development. The technology enables the production of consistent cell models for applications such as CRISPR screening, electrophysiology, and immunocytochemistry.
Fliar Intelligence Index™ 74how this company ranks against its industry peers
Growth
top 17%Funding
top 23%News
top 29%Moat
top 31%Fin. health
top 38%Talent
top 38%Growth: Headcount 13 → 52 (+300%) across vintages · Revenue +41% YoY · Fresh capital in last 24 mo
Funding: Raised $186M across 7 rounds · 7 rounds over 9 yrs (0.8/yr) · Last round Series C (Jan 2026)
News: 4 BI events in 12 mo (of 7 tracked, 3 types) · +300% YoY · Top themes: Funding, Layoffs
Audience (LinkedIn): 28k LinkedIn followers — 4.0% of this cohort's audience
Activity (LinkedIn): 3 product launches announced in 12 mo
Funding rounds
- Jan 2026Series C$50M
- Dec 2024Series B$30M
- Dec 2021Series B$37.2M
- Sep 2021Series B$103M
Founders & team
Investors
Resilience, Puhua Capital, Charles River Laboratories, Foresite Capital, Arch Venture Partners, Metaplanet
Tech stack
Apple Icloud MailBootstrapCart FunctionalityCloudflareCloudflare Bot ManagementCore-Js
#7
Series B · Cambridge, England · founded 2019 · 25 employees$49Mraised▾
Series B · Cambridge, England · founded 2019 · 25 employees
Developer of single-cell functional analysis using a droplet-based platform. The technology uses light rays to precisely control picoliter-scale droplets, enabling scalable assays for drug discovery, therapeutics, and basic research. The system facilitates sequential assays and the real-time dispensing of cells for downstream applications. It supports research into biomolecule secretion, cell-cell communication, and targeted cell killing mechanisms. The platform allows for the precise control of droplet merging to characterize individual cell responses.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Funding
top 28%Growth
top 36%Talent
top 38%Moat
bottom 48%Tech
bottom 46%Global
bottom 39%Funding: Raised $49.0M across 7 rounds · 7 rounds over 3 yrs (2.3/yr) · Last round Series B (Apr 2026)
Growth: Headcount 10 → 25 (+150%) across vintages · Revenue -5% YoY · Fresh capital in last 24 mo
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Audience (LinkedIn): 6k LinkedIn followers
Funding rounds
- Apr 2026Series B$27M
- Aug 2023Series B$49M
- Dec 2022Series B$25.1M
- Mar 2022Series A$14.2M
Founders & team
Investors
M Ventures, Arch Venture Partners, Illumina Ventures, OMX Ventures, ND Capital, Longwall Venture Partners
#8
Series C · London, England · founded 2015 · 40 employees$106.5Mraised▾
Series C · London, England · founded 2015 · 40 employees
Developer of modular lab automation platforms for biological research workflows. This system integrates hardware and software to orchestrate laboratory processes, including sample handling and instrument management. The platform utilizes node-based design tools and software development kits to enable workflow configuration and simulation. It supports connectivity with external data systems and analytical models to facilitate automated execution of experimental protocols. The hardware components are configurable to accommodate various instruments and laboratory layouts, allowing for the management of multiple concurrent tasks.
Fliar Intelligence Index™ 64how this company ranks against its industry peers
Funding
top 25%Product
top 25%Tech
top 27%Moat
top 31%Innovation
top 32%Fin. health
top 33%Funding: Raised $107M across 8 rounds · 8 rounds over 11 yrs (0.7/yr) · Last round Series C (Jan 2026)
Product: 7 distinct product lines · Company stage: Series C
Tech: 55 technologies across 6/8 capability areas · Cloud: Amazon S3, Amazon Web Services · Devops: Varnish
Audience (LinkedIn): 19k LinkedIn followers — 2.8% of this cohort's audience
Activity (LinkedIn): 1 partnerships (incl. Automata) announced in 12 mo
Funding rounds
- Jan 2026Series C$45M
- Oct 2023Series B$40M
- Feb 2022Series B$50M
- Mar 2019Series A$7.4M
Founders & team
Investors
Dimension, Octopus Ventures, Hummingbird Ventures, Isomer Capital, Possible Ventures, Aldea Ventures
Tech stack
Amazon Web ServicesApple Icloud MailClickceaseCloudflareCloudflare Bot ManagementCookiebot
#9
Series D · Cambridge, England · founded 2016 · 76 employees$273Mraised▾
Series D · Cambridge, England · founded 2016 · 76 employees
Developer of therapeutics targeting the deoxyribonucleic acid damage response in cancer. These treatments focus on inhibiting specific enzymes involved in cellular repair mechanisms to induce damage within malignant tissues. The approach utilizes small-molecule inhibitors to disrupt survival pathways in tumor cells. Research efforts concentrate on identifying biological targets that regulate replication stress and genomic stability. These therapeutic candidates are evaluated for use as monotherapies or in combination with other agents to address solid tumors.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Funding
top 24%Talent
top 28%Moat
top 31%Tech
top 49%Market
top 50%Growth
bottom 46%Funding: Raised $273M across 4 rounds · 4 rounds over 10 yrs (0.4/yr) · Last round Series D (Nov 2025)
Talent: 4 named leaders on record · 3 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Funding rounds
- Nov 2025Series D$115M
- Jul 2021Series C$153M
- Aug 2018Series B$84M
- Sep 2016Series A$36M
Founders & team
Investors
Andera Partners, Life Sciences Partners, Novartis, Arix Bioscience, SV Health Investors, IP Group
Tech stack
BootstrapCloudflareCloudflare Bot ManagementCookie InformationFont AwesomeGodaddy
#10
Series A · Cambridge, England · founded 2019$86.9Mraised▾
Series A · Cambridge, England · founded 2019
Biotechnology company developing next‑generation antibody therapies. The company focuses on creating next-generation antibody therapies. Their lead asset targets ATTR cardiomyopathy, a form of amyloidosis. The antibody is designed to selectively remove established amyloid fibrils.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Funding
top 23%Patents
top 47%Talent
bottom 49%Global
bottom 48%Innovation
bottom 45%Funding: Raised $86.9M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series A (Mar 2026)
Patents: 6 patents matched (strict assignee match) · 6 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 1k LinkedIn followers
Funding rounds
- Mar 2026Series A$86.9M
Founders & team
Investors
Frazier Life Sciences, F-Prime Capital, Qiming Venture Partners, SR One, Cambridge Enterprise, Cambridge Innovation Capital
#11
Series A · London, England · founded 2019 · 7 employees$31Mraised▾
Series A · London, England · founded 2019 · 7 employees
Provider of an AI-based hearing health diagnosis device for medical professionals. The company has developed a portable hearing assessment device for the screening of the hearing abilities of a person. It has another wax removal tool along with the device that removes was from the ear using micro-suction technology. The device can analyze and diagnose the hearing capability of an individual and the data can be shared on other platforms with healthcare professionals.
Fliar Intelligence Index™ 57how this company ranks against its industry peers
Growth
top 28%Funding
top 32%Talent
top 33%Tech
top 41%AI
top 45%Product
bottom 48%Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo
Funding: Raised $31.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) · Last round Conventional Debt (May 2026)
Talent: 3 named leaders on record · 2 C-suite/founder profiles curated
Audience (LinkedIn): 5k LinkedIn followers
Funding rounds
- May 2026Conventional Debt$2.7M
- Apr 2023Series A$23M
- Feb 2022Seed$8M
Founders & team
Investors
Octopus Ventures, Dara Capital, Rezayat Group, Innovateuk, Myelin, PUBLIC
Tech stack
Apple Icloud MailCloudflareCloudflare Bot ManagementCodemirrorCore-JsFancybox
#12
Series A · Kent, England · founded 2014 · 6 employees$64.9Mraised▾
Series A · Kent, England · founded 2014 · 6 employees
Developer of immunotherapeutics to treat infectious diseases. The company has proprietary Alphamer technology based on "programmable immunity" in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight the infections.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Funding
top 26%Growth
top 35%Moat
top 36%Patents
top 46%Talent
bottom 49%Innovation
bottom 42%Funding: Raised $64.9M across 12 rounds · 12 rounds over 11 yrs (1.1/yr) · Last round Series A (Feb 2026)
Growth: Fresh capital in last 24 mo
Moat: Editorial + unicorn rating 4/10 · IP moat: 50 patents · Soonicorn
Audience (LinkedIn): 3k LinkedIn followers
Funding rounds
- Feb 2026Series A$8.1M
- Jul 2025Grant (prize money)$5.1M
- Nov 2024Grant (prize money)$1.3M
- Jul 2023Series A$11.5M
Founders & team
Investors
Kent County Council, EJ Capital, Wren Capital, Discovery Park, Renaissance Capital Partners, Animatrix Capital Llp
Tech stack
CookiebotGodaddyGoogle AnalyticsHstsJqueryMicrosoft 365
Funding & investor landscape
$32.2Btotal disclosed funding
1,088companies funded
3,216disclosed rounds
24rounds last 90 days
Most active investors
Gov91 rounds
Notable founders
Demis Hassabis
Founder & CEO · Isomorphic Labs
Azim Surani
Co-Founder · CellCentric
Will West
Co-Founder & CEO · CellCentric
Eric Miska
Co-Founder & Director · STORM Therapeutics
Tony Kouzarides
Co-Founder & Director · STORM Therapeutics
James McIlroy
Founder & CEO · Enterobiotix
Natalie Mount
CEO · Cytospire Therapeutics
Mark Kotter
Co-Founder · Bit.bio
Przemek Obloj
Chief Executive Officer · Bit.bio
Cameron Frayling
Founder · Lightcast
Paul Loeffen
Chief Executive Officer · Lightcast
Mostafa ElSayed
Co-Founder & CEO · Automata
Prism market signals · United Kingdom · country-scoped Prism corpus, 709,332 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · United Kingdom
How research on Biotechnology is moving in the United Kingdom
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,508 United Kingdom-affiliated papers.
research sentiment over time
200820152026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and steady — the enthusiastic (strongly-positive) share moved 44% → 43% across 2008–2026.
top research entities
- Imperial College London70
- University College London67
- University of Cambridge54
- University of Edinburgh54
- University of Oxford48
leading researchers
Pratyush Mishra · Yang Yu · Boyan Zhang · Xianzhe Jiang · Yi Cui · Yuqing Shang · Vikas Kumar · Yiu Lam
▲
Breakthroughs427 · 28%
▼ 31%→28% share
▼0.9× share momentum0 median citations79% since 2021mostly empirical
Messenger RNA and Transcription research newly emerged, while Gene topic surged 4→31, signalling intensifying genomic-decoding focus.
rising sub-themes (early→recent)
- Gene4→31
- Population1→15
- Mutation1→13
- Chromatin1→11
- Mutant2→12
Newly emergingTranscription (linguistics) 0→19 · Messenger RNA 0→15 · Genome 0→12
Landmark Biomedical photoacoustic imaging · 2,130 cites
◆
Advancements509 · 34%
▲ 24%→36% share
▲1.5× share momentum0 median citations85% since 2021mostly empirical
Advancements field-share rose 24→36%; Antimicrobial research climbed 1→22 alongside brand-new Metagenomics, indicating accelerating antimicrobial-resistance investigation.
rising sub-themes (early→recent)
- Gene2→35
- Antimicrobial1→22
- Bacteria1→17
- Downregulation and upregulation1→17
- Antibody3→19
Newly emergingMicroorganism 0→14 · Fermentation 0→14 · Metagenomics 0→13
Landmark Microtiter Dish Biofilm Formation Assay · 2,147 cites
▼
Concerns322 · 21%
▼ 32%→18% share
▼0.6× share momentum0 median citations68% since 2021mostly reviews
Agriculture concern papers grew 9→18 with brand-new Outbreak and Malaria signals, suggesting rising biosecurity and crop-disease pressure.
rising sub-themes (early→recent)
- Production (economics)3→14
- Antimicrobial4→14
- Agriculture9→18
- Sustainability1→10
- Food safety2→11
Newly emergingMalaria 0→7 · Risk assessment 0→6 · Outbreak 0→6
Landmark Antibiotic resistance: a rundown of a global crisis · 2,496 cites
RESEARCH HOTSPOTS · United Kingdom
Where biotechnology is researched across United Kingdom
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
London258 · +0.43
Oxford75 · +0.46
Edinburgh69 · +0.43
Cambridge61 · +0.61
Glasgow34 · +0.44
Manchester28 · +0.57
Birmingham27 · +0.51
Bristol20 · +0.42
PATENT SIGNAL · United Kingdom
Who's filing biotechnology patents in the United Kingdom
United Kingdom biotechnology patent filing is accelerating — 35,956 filings from 8,000 assignees (2016–2025), led by Medimmune, Glaxo Group, UCL Business; annual filings 2688→3463.
35,956 filings8,000 assigneespeak 4311/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Medimmune2939
- Glaxo Group1583
- UCL Business1576
- UNIV Oxford Innovation1145
- Glaxosmithkline IP DEV997
- Medical RES Council948
- Cambridge Entpr859
- Kymab850
Common questions
How many Life Sciences companies are there in United Kingdom?
Radar tracks 2540 indexable Life Sciences companies headquartered in United Kingdom that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in United Kingdom?
The Life Sciences companies in United Kingdom on this list have raised a combined $32.2B in disclosed equity funding across 1088 funded companies.
Which is the highest-funded Life Sciences company in United Kingdom?
Isomorphic Labs is the highest-funded Life Sciences company in United Kingdom, with $2.7B in disclosed equity funding.
How many Life Sciences companies in United Kingdom are funded?
1088 of the 2540 Life Sciences companies in United Kingdom on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in United Kingdom?
3 Life Sciences companies in United Kingdom on this list are valued at $1B or more.
Who are the top investors in United Kingdom Life Sciences companies?
The most active investors in United Kingdom Life Sciences companies on this list include Europa, Gov, Scottish Enterprise, Ukri, Oxford University Innovation.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.